{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:24:27Z","timestamp":1791404667511,"version":"4.3.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CytoSorbents Inc. US Monmouth Junction NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The CytoSorb therapy in COVID-19 (CTC) registry evaluated the clinical performance and treatment parameters of extracorporeal hemoadsorption integrated with veno-venous extracorporeal membrane oxygenation (VV ECMO) in critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS) and respiratory failure under US FDA Emergency Use Authorization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Multicenter, observational, registry (NCT04391920).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Intensive care units (ICUs) in five major US academic centers between April 2020 and January 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>A total of 100 critically ill adults with COVID-19-related ARDS requiring VV ECMO support, who were treated with extracorporeal hemoadsorption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>None.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and main results<\/jats:title>\n                    <jats:p>\n                      Baseline demographics, clinical characteristics, laboratory values and outcomes were recorded following individual ethics committee approval at each center. Detailed data on organ support utilization parameters and hemoadsorption treatments were also collected. Biomarker data were collected according to the standard practice at each participating site, and available values were compared before and after hemoadsorption. The primary outcome of mortality was evaluated using a time-to-event analysis. A total of 100 patients (63% male; age 44\u2009\u00b1\u200911\u00a0years) were included. Survival rates were 86% at 30\u00a0days and 74% at 90\u00a0days. Median time from ICU admission to the initiation of hemoadsorption was 87\u00a0h and was used to define two post hoc groups:\u2009\u2264\u200987\u00a0h (group-early start,\n                      <jats:italic>G<\/jats:italic>\n                      <jats:sub>E<\/jats:sub>\n                      ) and\u2009&gt;\u200987\u00a0h (group-late start,\n                      <jats:italic>G<\/jats:italic>\n                      <jats:sub>L<\/jats:sub>\n                      ). After the start of hemoadsorption, patients in the\n                      <jats:italic>G<\/jats:italic>\n                      <jats:sub>E<\/jats:sub>\n                      versus\n                      <jats:italic>G<\/jats:italic>\n                      <jats:sub>L<\/jats:sub>\n                      had significantly shorter median duration of mechanical ventilation (7 [2\u201326] vs. 17 [7\u201337] days,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02), ECMO support (13 [8\u201324] vs. 29 [14\u201338] days,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.021) and ICU stay (17 [10\u201340] vs 36 [19\u201355] days,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). Survival at 90\u00a0days\u00a0in\n                      <jats:italic>G<\/jats:italic>\n                      <jats:sub>E<\/jats:sub>\n                      was 82% compared to 66% in G\n                      <jats:sub>L<\/jats:sub>\n                      (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.14). No device-related adverse events were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In critically ill patients with severe COVID-19-related ARDS treated with the combination of VV-ECMO and hemoadsorption, 90-day survival was 74% and earlier intervention was associated with shorter need for organ support and ICU stay. These results lend support to the concept of \u201cenhanced lung rest\u201d with the combined use of VV-ECMO plus hemoadsorption in patients with ARDS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13054-023-04517-3","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T13:01:33Z","timestamp":1687179693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry"],"prefix":"10.1186","volume":"27","clinical-trial-number":[{"clinical-trial-number":"nct04391920","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"J. W. Awori","family":"Hayanga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucian","family":"Durham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Garrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deane","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Molnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Scheier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthymios N.","family":"Deliargyris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Moazami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"key":"4517_CR1","unstructured":"WHO Coronavirus (COVID-19) Dashboard. Available online at: https:\/\/covid19.who.int\/. Accessed Aug 20 2022."},{"issue":"10229","key":"4517_CR2","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033\u20134.","journal-title":"Lancet"},{"issue":"6490","key":"4517_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.abb8925","volume":"368","author":"JB Moore","year":"2020","unstructured":"Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473\u20134.","journal-title":"Science"},{"issue":"20","key":"4517_CR4","doi-asserted-by":"publisher","first-page":"5990","DOI":"10.3390\/jcm11205990","volume":"11","author":"A Akil","year":"2022","unstructured":"Akil A, Napp LC, Rao C, Klaus T, Scheier J, Pappalardo F. Use of CytoSorb\u00a9 hemoadsorption in patients in veno-venous ECMO support for severe acute respiratory distress syndrome: a systematic review. J Clin Med. 2022;11(20):5990.","journal-title":"J Clin Med"},{"issue":"7","key":"4517_CR5","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1080\/13645706.2022.2104617","volume":"31","author":"A Nierhaus","year":"2022","unstructured":"Nierhaus A, Morales J, Wendt D, Scheier J, Gutzler D, Jarczak D, et al. Comparison of the CytoSorb((R)) 300 mL and Jafron HA380 hemoadsorption devices: an in vitro study. Minim Invasive Ther Allied Technol. 2022;31(7):1058\u201365.","journal-title":"Minim Invasive Ther Allied Technol"},{"issue":"8","key":"4517_CR6","doi-asserted-by":"publisher","first-page":"773461","DOI":"10.3389\/fmed.2021.773461","volume":"20","author":"T Song","year":"2021","unstructured":"Song T, Hayanga J, Durham L, Garrison L, McCarthy P, Barksdale A, et al. CytoSorb therapy in COVID-19 (CTC) patients requiring extracorporeal membrane oxygenation: a multicenter, retrospective registry. Front Med. 2021;20(8):773461.","journal-title":"Front Med"},{"key":"4517_CR7","unstructured":"CytoSorb 300 mL Device: Authorized by FDA for Emergency Treatment of COVID-19. (2020). Available online at: https:\/\/www.fda.gov\/media\/136866\/download. Accessed Aug 16 2022."},{"key":"4517_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13054-017-1662-9","volume":"21","author":"K Kogelmann","year":"2017","unstructured":"Kogelmann K, Jarczak D, Scheller M, Druner M. Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care. 2017;21:74.","journal-title":"Crit Care"},{"key":"4517_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s10047-017-0967-4","volume":"20","author":"S Friesecke","year":"2017","unstructured":"Friesecke S, Stecher S, Gross S, Felix SB, Nierhaus A. Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study. J Artif Organs. 2017;20:252\u20139.","journal-title":"J Artif Organs"},{"key":"4517_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jcrc.2018.11.003","volume":"49","author":"F Hawchar","year":"2019","unstructured":"Hawchar F, L\u00e1szl\u00f3 I, \u00d6veges N, Tr\u00e1sy D, Ondrik Z, Molnar Z. Extracorporeal cytokine adsorption in septic shock: a proof of concept randomized, controlled pilot study. J Crit Care. 2019;49:172\u20138.","journal-title":"J Crit Care"},{"issue":"1","key":"4517_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5492\/wjccm.v9.i1.1","volume":"9","author":"Y Mehta","year":"2020","unstructured":"Mehta Y, Mehta C, Kumar A, George JV, Gupta A, Nanda S, et al. Experience with hemoadsorption (CytoSorb\u00ae) in the management of septic shock patients. World J Crit Care Med. 2020;9(1):1\u201312.","journal-title":"World J Crit Care Med"},{"issue":"13","key":"4517_CR12","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.3390\/jcm10132939","volume":"10","author":"K Kogelmann","year":"2021","unstructured":"Kogelmann K, Hubner T, Schwameis F, Druner M, Scheller M, Jarczak D. First evaluation of a new dynamic scoring system intended to support prescription of adjuvant cytosorb hemoadsorption therapy in patients with septic shock. J Clin Med. 2021;10(13):2939.","journal-title":"J Clin Med"},{"issue":"12","key":"4517_CR13","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3390\/biomedicines8120539","volume":"8","author":"C Rugg","year":"2020","unstructured":"Rugg C, Klose R, Hornung R, Innerhofer N, Bachler M, Schmid S, et al. Hemoadsorption with CytoSorb in septic shock reduces catecholamine requirements and in-hospital mortality: a single-center retrospective \u2018genetic\u2019 matched analysis. Biomedicines. 2020;8(12):539.","journal-title":"Biomedicines"},{"issue":"10307","key":"4517_CR14","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/S0140-6736(21)01960-7","volume":"398","author":"RP Barbaro","year":"2021","unstructured":"Barbaro RP, MacLaren G, Boonstra PS, Combes A, Agerstrand C, Annich G, et al. Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international extracorporeal life support organization registry. Lancet. 2021;398(10307):1230\u20138.","journal-title":"Lancet"},{"key":"4517_CR15","unstructured":"Extracorporeal Life Support Organization (ELSO): COVID-19 Registry Dashboard. Available online at: https:\/\/www.elso.org\/registry\/fullcovid-19registrydashboard.aspx. Accessed Nov 08 2022."},{"issue":"6","key":"4517_CR16","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1016\/j.jtcvs.2021.04.089","volume":"163","author":"O Saeed","year":"2022","unstructured":"Saeed O, Tatooles AJ, Farooq M, Schwartz G, Pham DT, Mustafa AK, et al. Characteristics and outcomes of patients with COVID-19 supported by extracorporeal membrane oxygenation: a retrospective multicenter study. J Thorac Cardiovasc Surg. 2022;163(6):2107\u201316.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"4517_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1186\/s13054-020-03130-y","volume":"24","author":"M Rieder","year":"2020","unstructured":"Rieder M, Wengenmayer T, Staudacher D, Duerschmied D, Supady A. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation. Crit Care. 2020;24:435.","journal-title":"Crit Care"},{"issue":"7","key":"4517_CR18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1177\/03913988221103287","volume":"45","author":"A Akil","year":"2022","unstructured":"Akil A, Ziegeler S, Rehers S, Ernst EC, Fischer S. Blood purification therapy in patients with severe COVID-19 requiring veno-venous ECMO therapy: a retrospective study. Int J Artif Organs. 2022;45(7):615\u201322.","journal-title":"Int J Artif Organs"},{"issue":"11","key":"4517_CR19","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1164\/rccm.202011-4140LE","volume":"203","author":"G Lebreton","year":"2021","unstructured":"Lebreton G, Dorgham K, Quentric P, Combes A, Gorochov G, Schmidt M. Longitudinal cytokine profiling in patients with severe COVID-19 on extracorporeal membrane oxygenation and hemoadsorption. Am J Respir Crit Care Med. 2021;203(11):1433\u20135.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"4517_CR20","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-2600(21)00177-6","volume":"9","author":"A Supady","year":"2021","unstructured":"Supady A, Weber E, Rieder M, Lother A, Niklaus T, Zahn T, et al. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial. Lancet Respir Med. 2021;9(7):755\u201362.","journal-title":"Lancet Respir Med"},{"key":"4517_CR21","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/s41598-021-81300-w","volume":"11","author":"X He","year":"2021","unstructured":"He X, Yao F, Chen J, Wang Y, Fang X, Lin X, et al. The poor prognosis and influencing factors of high D-dimer levels for COVID-19 patients. Sci Rep. 2021;11:1830.","journal-title":"Sci Rep"},{"issue":"2","key":"4517_CR22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1159\/000526446","volume":"52","author":"D Jarczak","year":"2023","unstructured":"Jarczak D, Roedl K, Fischer M, de Heer G, Burdelski C, Frings DP, et al. Effect of hemadsorption therapy in critically Ill patients with COVID-19 (CYTOCOV-19): a prospective randomized controlled pilot trial. Blood Purif. 2023;52(2):183\u201392.","journal-title":"Blood Purif"},{"issue":"4\u20135","key":"4517_CR23","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1159\/000511725","volume":"50","author":"T Rampino","year":"2021","unstructured":"Rampino T, Gregorini M, Perotti L, Ferrari F, Pattonieri EF, Grignano MA, et al. Hemoperfusion with CytoSorb as adjuvant therapy in critically Ill patients with SARS-CoV2 pneumonia. Blood Purif. 2021;50(4\u20135):566\u201371.","journal-title":"Blood Purif"},{"issue":"11","key":"4517_CR24","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1111\/aor.14024","volume":"45","author":"AA Nassiri","year":"2021","unstructured":"Nassiri AA, Hakemi MS, Miri MM, Shahrami R, Koomleh AA, Sabaghian T. Blood purification with CytoSorb in critically ill COVID-19 patients: a case series of 26 patients. Artif Organs. 2021;45(11):1338\u201347.","journal-title":"Artif Organs"},{"issue":"5","key":"4517_CR25","doi-asserted-by":"publisher","first-page":"E101","DOI":"10.1111\/aor.13864","volume":"45","author":"A Alharthy","year":"2021","unstructured":"Alharthy A, Faqihi F, Memish ZA, Balhamar A, Nasim N, Shahzad A, et al. Continuous renal replacement therapy with the addition of CytoSorb cartridge in critically ill patients with COVID-19 plus acute kidney injury: a case-series. Artif Organs. 2021;45(5):E101\u201312.","journal-title":"Artif Organs"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04517-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-023-04517-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04517-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T05:08:17Z","timestamp":1698901697000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-023-04517-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,19]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4517"],"URL":"https:\/\/doi.org\/10.1186\/s13054-023-04517-3","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,19]]},"assertion":[{"value":"2 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prior to the collection of de-identified patient data from medical records and entry into the registry database, all participating US centers obtained written notice of approval from their respective Institutional Review Boards. In accordance with Good Clinical Practices (GCP) guidelines and applicable regulatory and institutional requirements, written informed consent from study participants was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"JS and ZM are full time employees of CytoSorbents Europe GmbH. END is a full-time employee of CytoSorbents Inc. US Monmouth Junction NJ, USA. The other authors state that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"243"}}